Corona: Drohen Flucht-Mutationen des Virus? - Was die neuen Virenvarianten über die Anpassung und Resistenzbildung von SARS-CoV-2 verraten scinexx.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scinexx.de Daily Mail and Mail on Sunday newspapers.
E-Mail
Credit: University of Cincinnati
PORTLAND, OR - A first-of-its-kind randomized clinical trial found that patients with pancreatic cancer didn t live any longer than expected after receiving pre-operative chemotherapy from either of the two standard regimens, according to trial results published in
JAMA Oncology.
While the trial findings did not show a direct patient benefit, they do show that it s possible to safely administer chemotherapy prior to pancreatic cancer surgery. They also pave the way for better treatment testing for this notorious killer. With no symptoms in the early stages, and few effective therapies, pancreatic cancer is the fourth-most deadly cancer type in the United States. According to the American Cancer Society, only 20 percent of pancreatic cancer patients are alive one year after diagnosis. After five years, only about 7 percent are alive.
New coronavirus variant could be problematic for vaccines, a second study in two days suggests
From CNN s Senior Medical Correspondent Elizabeth Cohen
As researchers around the world race to see if new coronavirus variants will pose a problem for the vaccines, a second study in two days says a variant from South Africa could possibly do just that.
The variant was first spotted in South Africa in October and has now been found in more than a dozen countries.
In both studies, the work was done in the lab and not in people, so more research is needed to gauge the true threat of the new variant.
Spotlight on Scott Furlan
Scott Furlan, pediatric oncologist
Dr. Scott Furlan, a pediatric oncologist at Fred Hutchinson Cancer Research Center, believes he was drawn to bone marrow transplantation because of the sheer complexity of the challenge.
“In pediatric transplant, each patient has a dizzying array of complex problems, each of which often has multiple solutions” Furlan said.
To treat his young cancer patients, he has to sort through raft of possibilities and options, while helping parents navigate the frightful choices that lie ahead of them.
“In pediatrics, we have the opportunity to develop long-lasting relationships and extraordinary connections with patients and families. I still talk with many patients and their parents a decade later,” Furlan said.